Skip to main content
. 2019 Apr;8(2):389–401. doi: 10.21037/tcr.2019.01.34

Figure 2.

Figure 2

Chemotherapy regimen concordance between WFO and Clinical use by breast cancer stage and molecular subtype in AC group (A,B) and NAC group (C,D). WFO, Watson for Oncology; AC, adjuvant chemotherapy; NAC, neoadjuvant chemotherapy therapy; A, Luminal A; B1, Luminal B/HER2 negative; B2, Luminal B/HER2 positive; H, HER2 positive; T, triple-negative.